Presentations Focus on the Implications of Metabolic Acidosis and CKD SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 9, 2020-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 24, 2020-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 5, 2020-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 29, 2020-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2020 financial results after the close of market on Wednesday, August 5, 2020 . Tricida will host a conference call and webcast at 4:30 pm Eastern Time

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 15, 2020-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 3, 2020-- Tricida, Inc. (Nasdaq: TCDA) announced that, due to public health concerns relating to the coronavirus pandemic (COVID-19) and to protect the health of its employees, directors and stockholders, its 2020 annual meeting of stockholders

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 2, 2020-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 41 st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 1:40 pm PT / 4:40 pm ET . Tricida will provide a company overview, business

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 22, 2020-- Tricida, Inc. (Nasdaq: TCDA) , a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 20, 2020-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 19, 2020-- Tricida, Inc. (Nasdaq: TCDA) today announced that it intends to offer $175.0 million aggregate principal amount of its Convertible Senior Notes due 2027 (the “Notes”) in a private offering (the “offering”) to qualified institutional